BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33189635)

  • 21. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of the RELAXin in acute heart failure study.
    Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
    Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serelaxin a novel treatment for acute heart failure.
    Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
    Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic effects of serelaxin in acute heart failure.
    Du XJ; Hewitson TD; Nguyen MN; Samuel CS
    Circ J; 2014; 78(3):542-52. PubMed ID: 24451687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF.
    Metra M; Davison BA; Gimpelewicz C; Carubelli V; Felker GM; Filippatos G; Greenberg BH; Hua TA; Liu Z; Pang PS; Ponikowski P; Severin TM; Voors AA; Wang Y; Cotter G; Teerlink JR
    Int J Cardiol; 2018 Feb; 253():91-96. PubMed ID: 29306479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.
    Beldhuis IE; Ter Maaten JM; Figarska SM; Damman K; Pang PS; Greenberg B; Davison BA; Cotter G; Severin T; Gimpelewicz C; Felker GM; Filippatos G; Teerlink JR; Metra M; Voors AA
    Clin Res Cardiol; 2023 Jul; 112(7):901-910. PubMed ID: 36656377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial.
    Gimpelewicz C; Metra M; Cleland JGF; Szecsödy P; Chang Wun CC; Boer-Martins L; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang P; Ponikowski P; Severin T; Voors AA; Teerlink JR
    Am Heart J; 2017 Aug; 190():113-122. PubMed ID: 28760204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
    Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
    Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
    Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study.
    Felker GM; Mentz RJ; Teerlink JR; Voors AA; Pang PS; Ponikowski P; Greenberg BH; Filippatos G; Davison BA; Cotter G; Prescott MF; Hua TA; Lopez-Pintado S; Severin T; Metra M
    Eur J Heart Fail; 2015 Dec; 17(12):1262-70. PubMed ID: 26333655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serelaxin for the treatment of heart failure.
    Moin DS; Bloom MW; Papadimitriou L; Butler J
    Expert Rev Cardiovasc Ther; 2016 Jun; 14(6):667-75. PubMed ID: 27045761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study.
    Meyer S; Teerlink JR; Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Qian M; Voors AA
    Clin Res Cardiol; 2017 Apr; 106(4):280-292. PubMed ID: 27838739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond.
    Cotter G; Milo O; Davison BA
    Curr Heart Fail Rep; 2014 Mar; 11(1):19-30. PubMed ID: 24363020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
    Díez J; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial.
    Spinar J; Jarkovsky J; Spinarova L; Vitovec J; Linhart A; Widimsky P; Miklik R; Zeman K; Belohlavek J; Malek F; Cihalik C; Spac J; Felsoci M; Ostadal P; Dusek L; Kettner J; Vaclavik J; Littnerova S; Monhart Z; Malek J; Parenica J;
    ESC Heart Fail; 2017 Feb; 4(1):8-15. PubMed ID: 28217307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF.
    Voors AA; Davison BA; Teerlink JR; Felker GM; Cotter G; Filippatos G; Greenberg BH; Pang PS; Levin B; Hua TA; Severin T; Ponikowski P; Metra M;
    Eur J Heart Fail; 2014 Nov; 16(11):1230-40. PubMed ID: 25287144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging role of serelaxin in the therapeutic armamentarium for heart failure.
    Varr BC; Maurer MS
    Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
    Kumar VA; Wilson SS; Ayaz SI; Levy PD
    Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry.
    Miró Ò; Gil V; Müller C; Mebazaa A; Bueno H; Martín-Sánchez FJ; Herrero P; Jacob J; Llorens P
    Clin Res Cardiol; 2015 Oct; 104(10):850-60. PubMed ID: 25903109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.